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Reviewer #1:  
The paper by Ruozi et al deal with formulation and characterization of streptomycin-loaded 
apoferritin nanoparticles. The paper is well executed and written. The data could be useful 
in translational application in particular that of microbiology and infective diseases. 
The findings should be of great interest to International Journal of Pharmaceutics 
readership. This is a solid piece of work that should be acceptable in the present form. 
 
 
 
 
Reviewer #2: The presented manuscript by Ruozi et al., with the title "Apoferritin nanocage 
as streptomycin drug reservoir: technological optimization of a new drug drug delivery 
systems" deals with the characterisation of novel apo-transferrin protein based particles, 
loaded with streptomycin, and explores optimal conditions for formulation and production. 
The authors test several apo-ferritin/streptomycin ratios and investigate features such as, 
among others, encapsulation efficacy, release kinetics, morphology, and size distribution. 
The study covers an interesting topic, the experiments are well designed and performed 
and the manuscript is well written. I therefore have only minor points that should be 
addressed before publication. 
 
Specific comments: 
1. The Material and Methods sections could benefit from more details and should be 
revised. Some examples: under 2. the authors state "After gently pipetting, apoferritin 
solution, monitored in term of size, surface charge and morphology (data not shown), was 
..." How was this done exactly? Further, "...water, previously acidified to pH 2, ..." How was 
this done? 
 
Thanks, we corrected and ameliorated.  
 
It would help the reader to (maybe in a table) provide the following information: In 3b, 1mL 
final apo-ferritin solution is obtained and further characterised. For the experiments used.  
 
What is the concentration (molarity) of streptomycin in the solution, what is the 
concentration encapsulated into nanocages, what is the concentration of apo-ferritin in the 
solution and the concentration of formed nanocages. The information is present in the 
manuscript but should be summarized.  
 
We corrected table I, in which there are yet information on encapsulation efficiency.  
Streptomycin in solution is concentrated at 0.05mg/mL. 
The Streptomycin concentration is expressed on content, as reported in table 1.  
So that, depending on the sample, as below: 
 
Samples mg Strep/100 
mg of Apo  
ApoStrep 1:10-D 0.67±0.01 
ApoStrep 1:10- 0.53±0.01 
*Response to Reviewers
DG 
ApoStrep 1:25-D 1.27±0.02 
ApoStrep 1:25-
DG 
1.07±0.01 
 
We added a table with the requested information. 
 
Sample Name Streptomycin concentration 
(mg/mL) 
Apoferritin amount (mg/mL) 
Streptomycin free solution 0.05mg/mL \ 
Apoferritin solution \ 15 mg/mL 
ApoStrep 1:10-DG See table I 10,3 (± 0,2) mg/mL 
ApoStrep 1:25-DG See table I 10,1 (± 0,3)  mg/mL 
ApoStrep 1:50-DG See table I 2,9 (± 0,2) mg/mL 
   
 
Table II: concentration of Apoferritin and Streptomycin. For Streptomycin content, please 
see Table I.  
 
 
2. The statistical evaluation needs a revision. Pairwise comparisons using t-test as stated 
in the Methods section is not appropriate. The evaluation should be done with ANOVA and 
in case of significant differences a post-hoc analysis such as Bonferroni. 
 
We repeated the statistical analysis using the suggested methods.  
 
3. In the results section, regarding the data shown in Figure 4 (page 136) the authors state 
a significant change in Zeta potential values. However, in the figure, no significance is 
indicated. 
 
Yes, we missed to insert the significance which is now inserted. 
 
4. In figure 3, it is hard to understand what comparisons are significant and marked by the 
"*" . Comparisons have to be done by ANOVA (see above) and significances labeled 
newly according to the new results. 
 
We tried to allow a more easy reading of significance in the new version of the figure. 
 
5. For the data presented in figure 7, can the authors extrapolate, when a full release 
would be achieved or perform the measurements for longer periods as the complexes 
seem quite stable.  
 
Yes, we agree with the referee, we can estrapolate the timing of a full release, and also we 
tested over time the release. We got a very a long period of release, and we agree with 
the referee, the complexes are quite stable and remain, as they are or slowing releasing 
Streptomycin for a long period.  
But since it is a formulative study, we are also aware that in vivo or even in vitro, this 
release would be affected by many factors which could strongly impact on the release (pH, 
enzymes, proteins) and therefore we decided to stop at 72 hrs only to show this kind of 
stability within 3 days.  
 
6. The conclusion section is rather short. I suggest to add a paragraph discussing the 
usability of the novel system in clinics. For example, what is the concentration of 
streptomycin used for treatment in the clinics and can the concentration be reached by 
apo-ferrtin nanocage delivery? How many injections are necessary? Does the slow 
release rate present an advantage or disadvantage? What is the amount of apo-ferrtitin 
nanocages necessary for a treatment of a patient and is the production feasible in this 
amount?  
 
We agree, we added a paragraph for the application of these system in clinics.  
 
Application of Apoferritin nanocages  
Despite extensive promises, much work is needed before clinical translation of APO as 
nanocages. As example, the study of the architecture and the structure of loaded APO are still 
at early stages and this situation represents the major limitation in translatability of APO to 
become DDS. This fact is principally due to unclear protocols for APO formulation and un-
clear chemico-physical, morphological and technological characterization and it frequently 
generates conflicting outputs.   Regarding Streptomycin application, the dose normally used in 
therapy is very high, and it will be impossible to reach such dose with APO nanocages, but on 
the other hand these systems are not designed for this scope. In fact, the possibility of 
exploiting nanocages able to be “safe” when circulating in the bloodstream, to slowly release 
the loaded drug and in a controlled manner and most of all to be engineered for a selective 
delivery should be considered as an added value and the real potential of these systems. In 
this work, we also tried to answer to the general lack of characterization of these system, as 
we firstly analyzed the possibility of formulating an active agent different from the 
“commonly used” agents for loading into APO (namely anticancer drugs). Moreover, we 
moved on analyzing the nature and narrow size of APO complex using analytical technique 
commonly used to characterize synthetic DDS as liposomes or nanoparticles (TEM, AFM, SEM, 
PCS, DSC etc) and applying these technologies to APO cages characterization. Aiming to 
improve the chances of translatability of APO as drug delivery systems, another point, which 
is very hard to be investigated, is related to the drug release and in particular to the changes 
in morphology and architecture of APO cage during and after the release of the drugs. To our 
knowledge, the technologies for this kind of characterization are still lacking, even if this focus 
strongly affects the biocompatibility of APO and the efficacy of treatment promoted by the 
released drug. A huge work should be done to better investigate on these aspects that need to 
be considered with a major interest. 
 
 
7. Carefully revise the manuscript for spelling and grammar. There are several errors and 
typos to be found throughout the manuscript. Fro example: 
- I suggest to change the title to "Apoferritin nanocage as streptomycin drug reservoir: 
technological optimization of a new drug delivery system" 
 
We agree with the referee and changed the title accordingly.  
 
- page 130, Introduction: please make sure to have no space between a number and % 
(75%) 
Done. 
-page 131, l. 1/2 ... to efficiently load drugs into ... 
corrected 
- page 136, 3rd paragraph "slightly" 
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- page 138 "be set to stabilize and modulate drug release, ..." 
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Abstract 
The aim of this study is to formulate and characterize streptomycin-loaded apoferritin nanoparticles 
(ApoStrep NPs) for their potential therapeutic use in bacterial resistant infections (i.e. tuberculosis). 
ApoStrep NPs were prepared by disassembly/reassembly process via pH method and changing 
apoferritin/drug molar ratio, purified by dialyses process also associated with gel filtration 
chromatography and characterized in their chemico-physical and technological parameters as yield, 
size distribution, polidispersivity, morphology, internal structure, zeta potential and loading efficacy. 
The results showed that spherical reproducible NPs could be obtained by using apoferritin/drug 
molar ratio lower than 1:25 and purification based on the combination of dialysis and gel filtration 
chromatography. Photon correlation spectroscopy, Uv–visible detection and electron microscopy 
showed the maintenance of the native apoferritin chemico-physical properties and structure. When 
formulated with apoferritin/drug 1:10 and 1:25 molar ratio, ApoStrep NPs showed remarkable 
encapsulation efficacy (35% and 28%, respectively) along with kinetic profile of drug delivery, 
approximately 15% at 37 °C in 72h, as evidenced by “in vitro” release experiments.  
Introduction 
Streptomycin is a broad spectrum aminoglycoside antibiotic typically used for the treatment of active 
tuberculosis, in combination with other antituberculosis agents. It is composed of a metabolic 
product of Streptomyces globisporus or another similar organism (Zumla et al., 2013). The major 
disadvantages of streptomycin consists of the inadequate penetration into the cells (due to its 
hydrophilicity) and rapid elimination from the blood stream (due to both efficient renal filtration and 
low level of association to plasma proteins) (Coessens et al., 1996). Moreover, different evidences 
describe a rapid bacterial resistance oocurring after Streptomycin treatment (75% of bacterial 
infectious including tubercoloses after one-four months of treatment). In most cases, this resistance 
has proven to be permanent. The importance of this problem is obvious, since further treatment 
with streptomycin were shown to be ineffective when the infecting organisms are drug-resistant 
(Pfuetze 1948). Above the development of novel antitubercolosis drugs, the creation of nanocarriers 
able to modulate drug delivery could be interestingly applied on drug-resistant epidemic. In fact, 
loading currently-used antitubercolosis drugs in nanocarriers-based formulations may shorten drug 
regimen duration, reduce frequency, and deliver medications more efficaciously. That way, a 
sustained release in both blood plasma as well as organ tissue, an increase in bioavailability, the 
reduction of patient default and the improvement of completion rates could be achieved. Taken 
together, all these advantages could lead to significant potential in the reduction of drug resistant 
tubercolosis cases (Smith 2011;  Asadi 2014).  
*Manuscript_REVISED
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An exciting improvement in drug delivery systems is represented by the possibility to efficiently load 
drugs into apoferritin nanocage. Apoferritin is the demineralized ferritin, composed of 24 
polypeptide subunits packed together to form a nanosphere of diameter ∼12 nm with an internal 
cavity ∼8 nm. This protein, as drug delivery system, was demonstrated to be a promising vehicle for 
targeted delivery of anticancer drugs (Arosio et al., 1991, Belletti et al., 2016). Generally, apoferritin 
may enhance drug selectivity for cell surfaces that express ferritin receptors, in particular ferritin-
binding sites and endocytotic pathways, which are expressed in all body cells and mainly in cells in 
rapid proliferation  (Burdo and Connor, 2003; Aisen 1991). Besides these aspects, apoferritin displays 
a number of advantages which could be exploited in the application toward drug-resistant 
tubercolosis epidemic. Ferritin is a major iron storage protein in humans; therefore its bio-
compatibility and biosafety are assured. Moreover, compared with other drug carriers (i.e. polymeric 
nanoparticles and liposomes), apoferritin is much smaller in size, thus leading to a longer circulation 
half-life. Despite the rigidness under physiological conditions, the ferritin nanocages can be broken 
down into subunits in acidic environment by a reversible process. In fact, when the pH is tuned back 
to neutral, the subunits are reconstituted into nanocage structures, almost in an intact manner 
(Maham et al.,  2009; Lin et al. 2011). Another advantage of apoferritin consists of its chemical 
“reactivity” since, as polymeric nanoparticles or liposomes, its surface can be easily modified to 
selectively direct to target site (Lin et al., 2011; Uchida et al., 2006; Dominguez-Vera 2004).  
Regarding the drug to be loaded into apoferritin, streptomycin (and particularly sulfate salt used in 
this research) possesses chemico-physical properties favorable for its location into the apoferritin 
nanocage, as its stability both in acids and in bases which is needed for formulative protocols 
requiring extreme pH values. Streptomycin is featured by a pKa of about 8 due to its secondary amino 
group and pKa ranging between 10 and 12 due to its two guanidine groups (Nys et al., 1971), 
providing a net positive charge both in physiological envirorment (pH 7) and during the formulation 
conditions (acidic pH), which favors electrostatic interaction with the apoferritin. Moreover, the MW 
(723 Da) is suitable for a stable internalization into protein cage avoiding drug loss across protein 
pores.  
In this paper, starting from preformulative evaluation on several parameters involved in 
disassembly/reassembly protocols (protein concentration, volume of reaction, pH during the process, 
ionic concentration in solution, temperature, stirring), we aimed to optimize the technological 
conditions needed for stable formulation of streptomicyn into apoferritin nanoparticles (ApoStrep 
NPs). Particularly, we focused on the impact of the molar ratio between apoferritin and drug (1:10, 
1:25, 1:50) and the purification process (by comparing dialyses and gel filtration chromatography) on 
drug loading, without changing the native structure of ApoStrep NPs. Then, we tried to consolidate 
the possibility of using apoferritin as drug delivery systems, not only for anticancer drugs (Belletti et 
al., 2016), but also for other kinds of drugs and active molecules.  
 
Materials and Methods 
 
1. Chemicals 
Apoferritin from equine spleen (solution ~40 mg/mL in 0.15 M sodium chloride) and streptomycin 
sulfate (MW= 728.69, water solubility =50 mg/mL) were purchased from Sigma Aldrich (Milan, Italy). 
Acetate cellulose dialysis membranes were purchased from CelluSepT1 (MWCO:3500, Membrane 
Filtration Products, Seguin, TX, USA). Sepharose CL-2B resin was purchased from Sigma Aldrich 
(Milan, Italy). Micro BCA protein assay kit composed of reagent A (alkaline tartrate-carbonate buffer), 
reagent B (bicinchonic acid solution) and reagent C (copper sulfate solution) was purcheased from 
Thermo Fisher Scientific Inc (Milan, Italy). All the solvents were of analytical grade; all other 
chemicals were commercially obtained and used without further purification. A MilliQ water system 
(Millipore, Bedford, MA, USA), supplied with distilled water, provided high-purity water (18 MΩ).  
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2. The encapsulation of streptomicine in apoferritin via pH changing method  
Streptomicyin was formulated in apoferritin NPs by disassembly/reassembly protocols accordingly 
with others adopted for different types of drugs (Xing et al., 2009; Cutrin et al., 2013; Dominguez-
Vera 2004; Blazkova et al., 2013; Liu et al., 2006; Kilic et al., 2012). For all preparations, apoferritin 
solution (15 mg/mL, 0.031 moles) was obtained by diluting apoferritin stock solution with water 
(370 µL diluted to 1 mL). After gently pipetting, apoferritin solution, monitored in term of size and 
surface charge (by means of PCS using a Zetasizer Nano ZS, Malvern UK as explained in paragraph 4a) 
and morphology (by means of trasmission electron microscopy (TEM) analysis as explained in 
paragraph 4b), was acidified to pH 2 (by addition of 800 µL of 0.1 N HCl), thus providing the 
disassociation of the apoferritin subunits. The sample was mixed by using magnetic stirring for 20 
min at 20°C. Then, different amounts of streptomycin sulfate (0.23, 0.57, 1.14 mg corresponding to 
0.31, 0.78 and 1.56 moli, respectivelly) solubilized in water (200 µL) and acidified to the pH 2 
(addition of HCl 0.1 N) was added dropwise to the protein solution to finally have 1:10, 1:25, 1:50 
apoferritin/drug molar ratios. As control sample, un-loaded apoferritin NPs were obtained following 
the same protocol previously exposed. Briefly, 200 µL of water, previously acidified to pH 2 (by 
addition of 0.1N HCl), was added to apoferritin solution (pH 2), simulating the same increase in 
volume of the case of addition of drug solution. 
In order to recover the native structure of the protein, the pH value of the solution was adjusted to 
pH 8 by adding NaOH 0.1 N (about 700 uL, under magnetic stirring). The final volume was adjusted to 
3 mL by adding water (basified to pH 8). The resulting solution was then stirred over 2 h at 25°C to 
allow the complete structural reassembly of the protein.  
The following formulations were obtained: CNTR (unloaded), ApoStrep 1:10, ApoStrep 1:25 and 
ApoStrep 1:50 (streptomicyn loaded NPs). 
3. Purification of samples 
3a. Dialysis procedure 
A membrane diffusion method was used to purify free streptomycin from streptomycin loaded NPs. 
Each sample (1 mL of suspension) was placed in the dialysis tube (MWCO 3500 Da), permeable to 
drug alone, but not to NPs. Tube was closed at both ends using closure devices (Spectrum Medical 
Industries, Houston, TX, USA), and placed in a solution at pH 8.0 (50 mL, 0.05M KH2PO4), gently 
shaken with a magnetic stirrer (100 rpm at 20±1°C for 4 h). Free drug diffused out of samples and 
through the membrane to the receiver phase. After this time, volume of receiving phase was then 
adjusted to 1 mL by using rotatory evaporation, filtered by a acetate cellulose (AC) membrane with 
0.2 µm porosity (Sartorious, Göttingen, Germany). 
Samples purified by dialysis were recovered and named: CNTR-D, ApoStrep 1:10-D, ApoStrep 1:25-D 
and ApoStrep 1:50-D. 
 
 
3b. Gel filtration chromatography 
The apoferritin samples, recovered after dialysis purification and adjusted to 1 mL as final volume, 
was eluted through the Sepharose CL-2B resin (Sigma Aldrich), packed in 17.5 x 1.5 cm column, by 
using 0.05M KH2PO4 solution (pH 8.0) as mobile phase. The separation efficiency was achieved by 
working in "flash mode", exerting a pressure of about 9 bar by means of an N2 flow. 40 fractions were 
collected, one of each minute starting from the 3rd min after deposition. Fractions were analyzed by 
UV spectrophotometry (Jasco V-530 UV-VIS Spectrophotometer, JASCO Europe, Cremella, Italy) by 
means of spectral scanning acquisition mode over the wavelength range 200-400 nm, with 5 min 
measurement intervals. The collected fractions containing apoferritin (identified by typical peak at 
280 nm-UV absorbance) were submitted to test by PCS, which highlighted the elution of apoferritin 
NPs within the interval 8-15 min (data not shown). These fractions were mixed and the volume 
adjusted to 3 mL (by rotary evaporation). Purified Samples obtained were named CTRL-DG, ApoStrep 
1:10 DG, ApoStrep 1:25 DG and ApoStrep 1:50 DG. 
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Fraction from 3 to 8 min containing aggregates were eliminated, while fractions from 16 to 43 min 
were mixed, concentrated in volume (1 mL) and then analyzed by HPLC to evaluate the presence of 
free streptomycin.   
 
4.Chemico-physical characterization of apoferritin NPs 
4a. Size, polydispersivity and zeta potential 
Polydispersivity index (PDI) and size distribution were determined by PCS using a Zetasizer Nano ZS 
(Malvern, UK; Laser 4 mW He–Ne, 633 nm, Laser attenuator Automatic, transmission 100–0.0003%, 
Detector Avalanche photodiode, Q.E. > 50% at 633 nm). The results were expressed both as intensity 
distribution, D(i), based on the scattered light intensity and as number distribution, D(n), based on 
the number of particles that peculiarly scattered light of all the particles. Both D(i) and D(n) identified 
the size below which is placed the 10% [D(10)], 50% [D(50)] and 90% [D(90)] of all the NPs. The zeta 
potential was measured using the same equipment with a combination of laser Doppler velocimetry 
and phase analysis light scattering (PALS). All the data are expressed as means of at least three 
determinations carried out for each preparation lot (three lots for each sample).  
4b. Morphology and structure  
The morphological and microstructural characterization of NPs was carried out through trasmission 
electron microscopy (TEM). A drop of each sample (CNTR-DG, ApoStrep 1:10 DG, ApoStrep 1:25 DG) 
was placed on a 200-mesh copper grid (TABB Laboratories Equipment, Berks, UK) and allowed to 
adsorb. The excess suspension was removed by filter paper, sample dried and then NPs were imaged 
with TEM, operating at an acceleration voltage of 200 kV (model JEM 2010; JEOL, Peabody, MA). 
Structure of apoferritin forming the NPs (CNTR-DG, ApoStrep 1:10 DG, ApoStrep 1:25 DG) was also 
investigated by evaluating the UV–vis absorption spectra performed on a Jasco V-530 UV-VIS 
spectrometer supplied with Spectra Manager II software. 
5. Apoferritin recovered after purification 
BCA assays were performed to achieve apoferritin quantification in CNTR-DG, ApoStrep 1:10 DG, 
ApoStrep 1:25 DG and ApoStrep 1:50 DG samples. Assays were performed using 96-well microplates 
and Pierce BCA Protein Assay Kit (Reagents A, B, C) (Rodano, Milano, Italia). Sample and reagent 
preparations were executed as indicated by manufacturing instructions. Briefly, in each well, an exact 
amount (150 μL) of samples (CNTR-DG, ApoStrep 1:10 DG, ApoStrep 1:25 DG or ApoStrep 1:50 DG) 
previously diluted 1:25 with 0.05M KH2PO4 solution (pH 8) or standard solutions (15 mg/mL of 
apoferritin solution) was added to the reagent mix (150 μL). Microplate was stored at 37°C for 2 h to 
allow the bicinchoninic acid/Cu2+ reaction with proteins, then the absorbance of the reaction product 
for the colorimetric quantification of proteins was measured at 570 nm, subtracting the absorbance 
reading of the blank by means of Microplate Reader Multiscan (Spectrum Finstruments®). The 
concentration was calculated using the calibration curve previously set up (linearity was assumed in 
the range of 0.46 -50 g/mL).  
Apoferrritin recovered after purification process/dialyses and gel filtration chromatography- 
(ApoYield [%]) is represented by the percent weight fraction of apoferritin evaluated by BCA assay 
compared with the total weight of apoferritin used for the preparation (Apo). 
The yield [%] was calculated as follows: 
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6.Technological characterization 
 
6a. Encapsulation efficiency 
The encapsulation efficiency of streptomycin into apoferritin NPs was calculated by indirect 
evaluation by HPLC analysis of the drug diffused through the dialysis membrane or eluted by gel 
filtration chromatography. The HPLC apparatus (JASCO Europe) used for this analysis is composed of 
a Model PU2089 pump provided with an injection valve with a 100 uL sample loop (Model 7725i, 
Jasco) and the UV/VIS detector (Jasco UV-975 Intelligent UV-VIS Detector). The analysis was 
performed in isocratic conditions, at a flow rate of 1 mL/min and at 30°C by reverse-phase 
chromatography (RP/HPLC) on C18 Acclaim Polar Advantage II column (150x46 mm, pore size 5µm, 
Agilent Technologies) equipped with a security guard. The mobile phase was KH2PO4 solution (pH 8.5, 
0.05M). Chromatographic peak area of the samples were recorded at 200 nm and analyzed using a 
JASCO software (JascoBorwin 1.5). The concentration was calculated using the calibration curve 
previously set up (linearity was assumed in the range of 0.5-83 g/mL). The amount of streptomycin  
loaded into NPs was evaluated by difference between the amount of total drug used and drug 
excluded by NPs. Then, the percentages of encapsulation efficiency (EE) was calculated using the 
following equations:  
 
Encapsulation Efficiency (EE%)= [drug loaded into apoferritin NPs / total amount of drug used to 
formulate] X 100. 
All the data are expressed as the means of at least three determinations. 
 
6b. In vitro release studies  
A membrane diffusion method was also used to evaluate the in vitro release studies of drug from 
apoferritin NPs. Briefly, 1 mL of Streptomycin (0.05mg/mL) or streptomicyn loaded NPs was placed 
into the dialysis tube (CelluSep, MWCO 3500). Dialysis tube was closed and placed in water (10 mL) 
and gently shaken with a magnetical stirrer in water (100 rpm at 37°C ± 0.1 °C). The drug diffused out 
of samples and through the membrane to the receiver phase. At defined time intervals (1, 3, 6, 24, 
48 and 72 h), a fixed volume (1 mL) of the receiving phase was withdrawn, the volume reduced at 
100 uL by evaporation and analyzed by HPLC for the drug content. The receiving phase tested was 
then replaced into the receiving medium to keep constant the final volume. The release study was 
carried out in triplicate for each sample.  
 
Statistical analysis 
All data were expressed as averages with standard deviations (SD). Statistical analysis was carried out 
using GraphPad Prism™. Data were assessed using either one-way or two-way ANOVA with a 
Bonferroni post hoc test. The significance was set at P<0.05. 
 
 
Results 
 
Streptomycin encapsulation into the apoferritin nanocage 
Figure 1. A) Schematic illustration of the encapsulation of streptomycin into apoferritin nanocage by 
disassembly/reassembly process via “pH changing method". Turbidity observed from pH 4 to 8 is 
possible due to a) protein precipitation (isoelectric point at pH 4.5);  b) protein aggregation induced 
by multivalent cations as streptomycin sulphate at pH 7.4; c) drug that could impact on the correct 
protein reassembling. 
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A schematic rappresentation of strepytomicine encapsulation into the apoferritin is shown in Figure 
1. In order to entrap the drug molecules into the apoferritin cage, the protein was disassembled and 
reassembled into the nanostructure via a “pH-changing method” as described in methods. The 
experimental conditions and parameters (buffer composition, concentration, volume of reaction, 
time of stirring,  final pH) were chosen on the basis of both preliminar investigations on 
disassembly/reassembly process of apoferritin alone and on the peculiar properties of drug (i.e. 
stability in the range pH 3-8 at room temperature). In detail, apoferritin and streptomycin were 
dissolved in MilliQ water and acidified with a HCl 0.1 N, not observing turbidity nor precipitation. 
During the reassembly process, by adding NaOH 0.1 N, once over the isoelectric point of the protein 
(pH 4.5), apoferritin precipitation took place, with difficult recovery of the monomeric form. This 
phenomenon was detected in the presence of high drug concentrations and probably due to the 
strong electrostatic attraction between positive charges of streptomycin and negative charges of the 
protein over its isoelectric point. 
Multivalent cations, such as streptomycin, could act as a bridge with protein molecules, thus 
reducing intermolecular repulsion and maybe causing aggregation (Weisenberg and Timasheff, 
1970). Alternatively, this bridge streptomycin-apoferritin may also induce incorrect interaction 
between protein subunits leading to wrong or incomplete reassembly (Figure 1).  
In order to reduce this protein instability, reassembly process must be continued until pH 8.0, 
therefore not stopping basification at pH 7.4. At this pH value, the drug loses one of its positive 
charges, with consequent reduction of its pro-aggregating effect, even maintaining stability (Oswald 
and Nielsen, 1947). 
Remarkably, this reassembling protocol was effective in avoiding protein precipitation only using 
protein/drug molar ratio lower than 1:50 ratio, while it was poorly efficacious doubling the amount 
of drug (data not shown).  
The polydispersity index (PDI) of samples after disassembly/reassembly of apoferritin with drug at 
different molar ratio (ApoStrep 1:10, ApoStrep 1:25 and ApoStrep 1:50) is reported in Figure 2. PDI 
values bigger than 0.3 suggest poor uniformity of all samples before purification process. Already 
disassembling/reassembling process of apoferritin carried out without drug seems to produce a 
sample (CNTR) with a multimodal distribution, presumably formed by monomers and aggregates.  
The heterogeneity of samples proportionally increased with the increase of streptomycin 
concentrations used in formulation. Dialysis process, which removes the excess of drug in solution, 
lead to the stabilization complexes (ApoStrep 1:10-D, ApoStrep 1:25-D) with PDI values similar to 
apoferritin alone ones (of about 0.4). On the contrary, dialysis process was ineffective on ApoStrep 
1:50–D, which tended to aggregate with an increase in PDI value up to 0.8. In order to more 
efficiently remove aggregates, all samples underwent to a double purification process by combining 
dyalises with gel filtration. For all samples (ApoStrep 1:10-DG, ApoStrep 1:25-DG, ApoStrep 1:50–
DG) PDI values decreased down to 0.3-0.35, indipendentetly from the protein:drug molar ratio used. 
Figure 2. PDI values of apoferritin NPs (CNTR, ApoStrep 1:10, ApoStrep 1:25, ApoStrep 1:50) after 
      formulation,       dialysis process (D) and        combining dialysis and gel filtration chromatography.  
    
  
Figure 3. Dimensional characterization of ApoStrep NPs. D(i) (panels a, c and e)  and D(n) (panels b, d 
and f) of samples after formulation (a and b), dialysis (c and d), and combining dialysis and gel 
filtration chromatography (e and f). Statistical analyses were performed: *p < 0.05 vs CNTR. 
 
As suggested by PDI values, ApoStrep NPs can be described by a multimodal distribution, with the 
presence of apoferritin NPs and aggregates. To describe the sample, both Di and Dn were analized. Di 
values, referred to scattering intensity, nicely identify the presence of aggregate since large particles 
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scatter much more light than small particles. On the contrary, Dn values clearly indicate the 
numerical distribution of the populations into the samples and therefore the most representative 
NPs population within the sample (organization of monomeric form of protein).  
During the reassembly process, even in absence of drug (CNTR, Figure 3a), the sample resulted 
composed by protein nanocage (correct reassembly, Di(50)= 57±17 nm) mixed with protein 
aggregates (uncorrect reassembly, Di(90)= 305±46 nm).  
Di(50) values of ApoStrep samples (ApoStrep 1:10, ApoStrep 1:25 and ApoStrep 1:50) proportionally 
increased in line with the increase of Streptomycin in solution, suggesting that a limit in drug 
concentration is present in order to preserve the integrity of apoferritin. The formulation obtained 
with 1:10 protein/drug molar ratio (ApoStrep 1:10) showed a Di(50) of 53±15 nm similar to the CNTR 
(without drug, Di(50)= 57±17nm), while already 1:25 protein/drug molar ratio formulation (ApoStrep 
1:25) slightly start aggregating (Di(50)= 100±20 nm). This aggregation effect becomes significant in 
1:50 protein/drug molar ratio (ApoStrep 1:50), with an increase of Di(50) at 220 ±60 nm value (Figure 
3a).  
Similarly, high values of Di90 and large S.D., representative of the presence of aggregates in 
suspension, slightly increased with the increasing of the drug into the formulation becoming higher 
that 1 uM and less reproducible at 1:50 protein/drug ratio. 
The simple incubation of drug and apoferritin at pH 8 is not able to induce aggregation (data not 
shown), confirming that the disassembly/reassembly process is responsible of the protein 
destabilization in presence of the drug.  
Dn values (Figure 3b), which are more representative of monomeric population of protein, are nicely 
in agreement with Di values. Thus, protein aggregation was detected only in presence of 
protein/drug 1:50 molar ratio (ApoStrep 1:50), while no significant differences in Dn values were 
observed for 1:10 (ApoStrep 1:10) and 1:25 (ApoStrep 1:25) protein/drug molar ratios with respect 
to the control preparation (CNTR), demonstrating structural stability of the formulated apoferritin.  
Purification of the sample from the excess of unloaded streptomycin lead to reduction of 
aggregation, as highlighted by Di values decrease (Figure 3c). No substantial differences in terms of 
Dn values were observed after purification by dialysis of the samples 1:10 and 1:25 molar ratio 
between protein and drug  (ApoStrep 1:10-D, ApoStrep 1:25-D), indicating that size distribution of 
the re-organized protein nanosctructure is poorly affected by the removal of the excess of drug or 
protein aggregates (Figure 3d).  Differently, the formulation obtained by using drug in large excess 
(ApoStrep 1:50-D) was not efficiently purified, maintaining a wide dimensional range of structures 
wrongly re-organized after loading/reassembly process.  
The removal of aggregates is obtained by coupling gel filtration chromatography to dialysis process. 
As evident in Figure 3e, for all the samples tested, the values of Di indicate a monomodal size 
distribution, referred to monomeric and monodisperse form of apoferritin nanostructure. 
Particularly, Di (50) values for the samples 1:10 and 1:25 molar ratio between protein and drug  
(ApoStrep 1:10-DG, ApoStrep 1:25-DG) begin to correlate with Dn values reaching under 30 nm. 
 
Figure 4 shows zeta potential values of apoferritin NPs obtained with different protein/drug molar 
ratio before and after the purification process. Regarding control sample (CNTR), high negative 
values of zeta potential on the surface on apoferritin (−50 ± 6 mV) confirmed high stability before 
and after the purification process. Zeta potential values significantly changed after the encapsulation 
process becoming less negative for all the molar ratio of tested complexes (from -20 to -37 mV) if 
compared to apoferritin alone. This fact is probably due to a relevant absorption of streptomycin on 
NPs surface. This data was confirmed by the restoring of more negative zeta values (ranging from -38 
mV and -55 mV) after removal of excess of drug molecules by dialysis. The combination of dialysis 
and gel filtration chromatography did not change those negative values observed after the 
purification with dialysis process alone.  
Figure 4. Zeta potential of apoferritin NPs (CNTR, ApoStrep 1:10, ApoStrep 1:25, ApoStrep 1:50) after             
       formulation,       dialysis process (D) and        combining dialysis and gel filtration chromatography.  
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As previously exposed, PCS analysis showed several concerns on formulations prepared with 1:50 
apoferritin/drug molar ratio, strongly affected by the presence of aggregates. The amount of protein 
evaluated by BCA assay in apoferritin NPs fraction eluted from column by gel filtration 
chromatography confirms the suitability of this sample. In fact, apoferritin in ApoStrep 1:50-DG 
sample was only around 20% of Apo ferritin used in formulation, while apoferritin recovered in 
ApoStrep 1:10-DG and ApoStrep 1:25-DG was higher and close to 70% for both samples (Table II). 
Therefore, ApoStrep 1:50-DG was excluded from the subsequent experiments. 
 
Table II: concentration of Apoferritin and Streptomycin. For Streptomycin content, please see Table I.  
In order to examine whether the structure of apoferritin changed after the encapsulation of 
streptomycin (Xing et al., 2009), we performed and compared the UV spectra of the CNTR-DG with 
ApoStrep1:10-DG and ApoStrep1:25-DG (Figure 5). Apoferritin alone and ApoStrep NPs exhibited 
similar spectral features with their characteristic absorption (close to 280 nm). This absorption arises 
from the amino acid residues with aromatic rings in apoferritin and its intensity linearly correlates 
with the concentration of protein (Stoscheck 1990). The results suggested that apoferritin drug 
complexes displayed structures similar to apoferritin alone and that encapsulation of streptomycin in 
the protein cavity barely affects the surface nature of apoferritin.  
Figure 5. UV spectra of CNTR-DG vs ApoStrep1:10-DG and  ApoStrep1:25-DG 
The assembly state of the ApoStrep NPs was investigated using TEM analyses. TEM images revealed 
that disassembly/reassembly process, carried out both with or without drug, produces constructs 
that retain the native ability to adopt a spherical cage-like structure. As shown in Figure 6a, related 
to sample CNTR-DG (obtained without drug and purified by dialyses and gel filtration 
chromatograpy), the absence of electron-spot in correspondence of the central cavity of the 
particles, typical of TEM analysis of ferritin (Massover 1993), and the elemental analysis performed 
on the samples demonstrates that the protein is free of iron normally located in its internal cavity, 
making the core available for a subsequent load of drugs. A much more contrasting corona that 
surrounds the protein may in fact identifiy the densest area of the protein wall, while the lighter 
interior area could indicate its cavity. No differences both in morphology and size were observed 
between CNTR-DG and streptomicine loaded samples by using TEM experiments (Figure 6c and d, as 
example we report only ApoStrep 1:25-DG). 
Figure 6. TEM analysis of apoferritin NPs a) images of CNTR-DG, b) EDX of CNTR-DG, c) images of 
ApoStrep 1:25-DG, d) magnification of ApoStrep 1:25-DG. 
 
Encapsulation Efficiency and in vitro drug release 
 
The quantification of the encapsulated streptomycin was performed by indirect evaluation of the 
unloaded drug, separated from ApoStrep NPs both after dialysis process and the combination of 
dialysis and gel filtration chromatography. Results are reported in Table 1. The amount of drug 
encapsulated in 100 mg of apoferritin is around 0.6 mg and 1.3 mg for ApoStrep1:10-D and ApoStrep 
1:25-D, respectively. Combining gel filtration chromatography, the amount of drug stably 
encapsulated slightly decreased to 0.5 mg and 1.0 mg, respectively. The encapsulation efficiency 
ranged from 30 to 40% in ApoStrep1:10-DG, while it is closed to 30% in ApoStrep1:25-DG, therefore 
confirming that the dialysis process is yet efficacious to purify the samples. 
Moreover, apoferritin exhibited a good control on streptomycin release; in fact, independently of 
samples tested, only 15% of encapsulated drug was released from protein nanocage over three days 
at 37°C, demonstrating higher stability of formulate products (Figure 7).  
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Figura 7. Drug release from apoferritin NPs. Values represent the mean of at least 3 experiments. 
Standard deviation is reported in brakects.  
Conclusion 
Apoferritin is one of the most investigated classes of proteins applicable in drug delivery. 
Notwithstanding,  only few studies investigated the ability of this nanocarrier in loading drugs of 
different activity than anticancer agents. In this paper, we demonstrated that the interaction 
between streptomycin sulfate and apoferritin obtained by changing pH values of preparation 
environment can lead to the formation of possible biocompatible drug delivery systems for the drug 
release of antimicrobial drugs as Streptomycin. The chemico-physical and technological 
characterization of ApoStrep NPs provided information about the operative parameters that should 
be set to stabilize and to modulate drug release, demonstrating that an usefull reassembly of 
apoferritin is greatly dependent both on the pH and the concentration of drug in solution. Only 
combining dialyses and gel filtration chromatography ApoStrep NPs were efficiently purified from un-
encapsulated drug and let free from aggregate; the majority of the entrapped drug molecules 
remained within cage (even with the stress of these purification procedures) with a good control on 
drug released. These preliminary data can be used for the design of new antrimicrobial delivery 
systems and can be also taken into account for the prediction of drug interactions within 
pharmaceutical formulations. 
Application of Apoferritin nanocages  
Despite extensive promises, much work is needed before clinical translation of APO as nanocages. As 
example, the study of the architecture and the structure of loaded APO are still at early stages and 
this situation represents the major limitation in translatability of APO to become DDS. This fact is 
principally due to unclear protocols for APO formulation and poor chemico-physical, morphological 
and technological characterization, frequently generating conflicting outputs. Regarding 
Streptomycin application, the dose normally used in therapy is very high, and it would be impossible 
to reach such doses with APO nanocages strategy. On the other hand, these systems are not 
designed for this scope. In fact, the possibility of exploiting nanocages able to be “safe” when 
circulating in the bloodstream, to slowly release the loaded drug and in a controlled manner and, 
most of all, to be engineered for a selective delivery should be considered as an added value and the 
real potential of these systems. In this work, we also tried to answer to the general lack of 
characterization of these systems, as we firstly analyzed the possibility of formulating an active agent 
different from the “commonly used” agents for loading into APO (namely anticancer drugs); then,  
we moved on analyzing the nature and narrow size of APO complex using analytical technique 
commonly used to characterize nanomedicine as liposomes or nanoparticles (TEM and PCS) and 
applying these technologies to APO cages characterization. Aiming to improve the chances of 
translatability of APO as drug delivery systems, another point, which is very hard to be investigated, 
is related to the drug release and in particular to the changes in morphology and architecture of APO 
cage during and after the release of the drugs. To our knowledge, the technologies for this kind of 
characterization are still lacking, even if this focus strongly affects the biocompatibility of APO and 
the efficacy of treatment promoted by the released drug. A huge work should therefore be done to 
better investigate on these aspects, that need to be considered with a major interest. 
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Table 1: loading capacity and encapsulation efficiency (EE) of ApoStrep D and ApoStrep DG 
samples 
 
Samples mg Strep/100 
mg of Apo  
EE% 
ApoStrep 1:10-D 0.67±0.01 44±5 
ApoStrep 1:10-
DG 
0.53±0.01 35±4 
ApoStrep 1:25-D 1.27±0.02 33±3 
ApoStrep 1:25-
DG 
1.07±0.01 28±1 
 
Table I
Sample Name Streptomycin concentration 
(mg/mL) 
Apoferritin amount (mg/mL) 
Streptomycin free solution 0.05mg/mL \ 
Apoferritin solution \ 15 mg/mL 
ApoStrep 1:10-DG See table I 10,3 (± 0,2) mg/mL 
ApoStrep 1:25-DG See table I 10,1 (± 0,3)  mg/mL 
ApoStrep 1:50-DG See table I 2,9 (± 0,2) mg/mL 
   
 
Table II: concentration of Apoferritin and Streptomycin. For Streptomycin content, please 
see Table I.  
Table II
 Figure 1. A) Schematic illustration of the encapsulation of streptomycin into apoferritin nanocage by 
disassembly/reassembly process via “pH changing method". Turbidity observed from pH 4 to 8 is possible 
due to a) protein precipitation (isoelectric point at pH 4.5);  b) protein aggregation induced by multivalent 
cations as streptomycin sulfate at pH 7.4; c) drug that could impact on the correct protein reassembling. 
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Figure 2. PDI values of apoferritin NPs (CNTR, ApoStrep 1:10, ApoStrep 1:25, ApoStrep 1:50) after 
      formulation,       dialysis process (D) and        combining dialysis and gel filtration chromatography.  
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Figure 3. Dimensional characterization of ApoStrep NPs. Di (panels a, c and e)  and Dn (panels b, d and f) of 
samples after formulation (a and b), dialysis (c and d), and combining dialysis and gel filtration 
chromatography (e and f).        D(10)          D(50)          D(90). Data were analyzed using a one-way ANOVA 
coupled with Bonferroni post hoc test. All values are expressed as mean ± SEM. *P<0.05 was the required 
statistical significance (vs CNTR). 
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Figure 4. Zeta potential of apoferritin NPs (CNTR, ApoStrep 1:10, ApoStrep 1:25, ApoStrep 1:50) after             
       formulation,       dialysis process (D) and        combining dialysis and gel filtration chromatography.  
Data were analyzed using a one-way ANOVA coupled with Bonferroni post hoc test. All values are expressed 
as mean ± SEM. *P<0.05 was the required statistical significance (vs “none”) 
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Figure 5.  UV spectra of CNTR-DG vs ApoStrep1:10-DG and  ApoStrep1:25-DG  
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Figure 6. TEM analysis of apoferritin NPs a)Images of CNTR-DG, b)EDX of CNTR-DG, c)images of ApoStrep 
1:25-DG, d) magnification of ApoStrep 1:25-DG. 
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 Figura 7. Drug released from apoferritin NPs. Values represent the mean of at least 3 
experiments. Standard deviation is reported in brakects. 
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